Cargando…
CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice
About 20% of prostate cancer (PCa) patients progress to metastatic disease. Metabolic syndrome (MeS) is a pathophysiological disorder that increases PCa risk and aggressiveness. C-terminal binding protein (CTBP1) is a transcriptional corepressor that is activated by high-fat diet (HFD). Previously,...
Autores principales: | Dalton, Guillermo Nicolás, Massillo, Cintia, Scalise, Georgina Daniela, Duca, Rocío, Porretti, Juliana, Farré, Paula Lucia, Gardner, Kevin, Paez, Alejandra, Gueron, Geraldine, De Luca, Paola, De Siervi, Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443782/ https://www.ncbi.nlm.nih.gov/pubmed/30931931 http://dx.doi.org/10.1038/s41419-019-1535-z |
Ejemplares similares
-
CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis
por: Farré, Paula L., et al.
Publicado: (2018) -
CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs
por: De Luca, Paola, et al.
Publicado: (2016) -
Adipose tissue from metabolic syndrome mice induces an aberrant miRNA signature highly relevant in prostate cancer development
por: Massillo, Cintia, et al.
Publicado: (2020) -
MiR-106b-5p: A Master Regulator of Potential Biomarkers for Breast Cancer Aggressiveness and Prognosis
por: Farré, Paula Lucía, et al.
Publicado: (2021) -
Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients
por: Duca, Rocío Belén, et al.
Publicado: (2022)